Literature DB >> 8039881

Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells.

T R Rhinehart-Jones1, A H Fortier, K L Elkins.   

Abstract

Both serum and spleen cells from mice immune to Francisella tularensis transfer protection to naive recipients. Here we characterize the mechanism of protection induced by transfer of immune mouse serum (IMS). IMS obtained 4 weeks after intradermal infection with 10(3) bacteria of the live vaccine strain (LVS) contained high levels of immunoglobulin G2 (IgG2a) and IgM (end point titers, 1:16,600 and 1:7,200, respectively) and little IgG1, IgG2b, or IgG3. LVS-specific antibodies were detected 5 days after intradermal infection, and reached peak levels by 2 weeks postinfection. Only sera obtained 10 days or more after sublethal infection, when IgG titers peaked, transferred protection against a challenge of 100 50% lethal doses (LD50s). Purified high-titer IgG anti-LVS antibody but not IgM anti-LVS antibody was responsible for transfer of protection against an intraperitoneal challenge of up to 3,000 LD50s. IMS had no direct toxic effects on LVS and did not affect uptake or growth of bacteria in association with peritoneal cells. One day after LVS infection, liver, spleen, and lung tissue from mice treated with IMS contained 1 to 2 log units fewer bacteria than did tissue from mice treated with normal mouse serum or phosphate-buffered saline. Between 2 and 4 days after infection, however, bacterial growth rates in tissues were similar in both serum-protected mice and unprotected mice. Bacterial burdens in IMS-treated, LVS-infected mice declined in infected tissues after day 5, whereas control animals died. This lag phase suggested that development of a host response was involved in complete bacterial clearance. In fact, transfer of IMS into normal recipients that were simultaneously treated with anti-gamma interferon and challenged with LVS did not protect mice from death. Further, transfer of IMS into athymic nu/nu mice did not protect against LVS challenge; protection was, however, reconstituted by transfer of normal T cells into nu/nu mice. Thus, "passive" transfer of protection against LVS with specific antibody is not passive but depends on a host T-cell response to promote clearance of systemic infection and protection against lethal disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039881      PMCID: PMC302937          DOI: 10.1128/iai.62.8.3129-3137.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

Review 1.  The use of intravenous immune globulin in immunodeficiency diseases.

Authors:  R H Buckley; R I Schiff
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

Review 2.  Immunity to mycobacteria.

Authors:  S H Kaufmann
Journal:  Res Microbiol       Date:  1990 Sep-Oct       Impact factor: 3.992

3.  Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera.

Authors:  L M Wetzler; K Barry; M S Blake; E C Gotschlich
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

4.  In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Authors:  D A Leiby; A H Fortier; R M Crawford; R D Schreiber; C A Nacy
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 5.  A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease.

Authors:  M M Simon; U E Schaible; R Wallich; M D Kramer
Journal:  Immunol Today       Date:  1991-01

6.  Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models.

Authors:  L B Givner
Journal:  Pediatrics       Date:  1990-12       Impact factor: 7.124

7.  The requirement for gamma interferon in resistance of mice to experimental tularemia.

Authors:  L S Anthony; E Ghadirian; F P Nestel; P A Kongshavn
Journal:  Microb Pathog       Date:  1989-12       Impact factor: 3.738

8.  Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice.

Authors:  U E Schaible; M D Kramer; K Eichmann; M Modolell; C Museteanu; M M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

9.  The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa.

Authors:  R B Markham; G B Pier; J R Schreiber
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

10.  Live vaccine strain of Francisella tularensis: infection and immunity in mice.

Authors:  A H Fortier; M V Slayter; R Ziemba; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  59 in total

1.  Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity.

Authors:  C M Bosio; K L Elkins
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

3.  Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis.

Authors:  Ravinder Kaur; Shan Chen; Maria T Arévalo; Qingfu Xu; Yanping Chen; Mingtao Zeng
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

4.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

5.  Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.

Authors:  Giang H Pham; Bibiana V Iglesias; Edmund J Gosselin
Journal:  Vaccine       Date:  2014-07-26       Impact factor: 3.641

6.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

7.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

8.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

9.  T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria.

Authors:  Carmen M Collazo; Anda I Meierovics; Roberto De Pascalis; Terry H Wu; C Rick Lyons; Karen L Elkins
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

10.  Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection.

Authors:  Dennis W Metzger; Sharon L Salmon; Girish Kirimanjeswara
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.